Integration of Charged Peptide Amphiphiles within Lipid Nanoparticles (LNPs) for Enhanced Targeted mRNA Delivery
Summary
Lipid nanoparticles (LNPs) play a pivotal role in mRNA-based therapy; however, achieving targeted delivery remains challenging. We developed an LNP platform integrating peptide amphiphiles (PAs) to exploit their dual bioactivity and electrostatic tunability. Two PAs, cationic C16TAT (derived from a cell-penetrating peptide) and anionic C16HA2 (based on an endosomolytic peptide), were co-assembled into LNPs. In vitro, C16TAT/LNPs significantly enhanced mRNA delivery across multiple cell lines via improved cellular uptake.
Lipid nanoparticles (LNPs) play a pivotal role in mRNA-based therapy; however, achieving targeted delivery remains challenging. We developed an LNP platform integrating peptide amphiphiles (PAs) to exploit their dual bioactivity and electrostatic tunability. Two PAs, cationic C16TAT (derived from a cell-penetrating peptide) and anionic C16HA2 (based on an endosomolytic peptide), were co-assembled into LNPs. In vitro, C16TAT/LNPs significantly enhanced mRNA delivery across multiple cell lines via improved cellular uptake. Due to the potent charge-modifying capacity of C16HA2, C16HA2/LNPs exhibit spleen-selective tropism in vivo, achieving >100-fold higher mRNA expression in the spleen than in the liver. While the commonly used surface-conjugated TAT-PEG-LNPs enhanced transfection in vitro, their in vivo performance was inferior relative to the C16TAT/LNP system due to the lack of stability, highlighting the advantage of PA integration. Critically, effective tissue targeting required substantial LNP charge alteration (pKa and zeta potential), which was achievable with C16HA2 but not C16TAT, likely due to the former's higher aggregation tendency. Dual PA-PEG modifications may improve spleen targeting but required formulation optimization. This work establishes a simple PA/lipid co-assembly approach as a robust method for modulating LNP tropism, advancing the rational design of targeted mRNA delivery systems.
Abstract from PubMed (PMID 42965882). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Mathematical modeling in mRNA therapeutics: towards a pathway to individualized treatment protocols
Molecular pharmaceuticsCombined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy
The Journal of clinical investigationA single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
